Aileron Therapeutics Announces FDA Acceptance of IND for ALRN-6924 as a Myelopreservation Agent in Patients with p53-mutant Cancer Treated with Chemotherapy June 27, 2019 - NASDAQ Companies 0 » View More News for June 27, 2019